Chart-Typ:
Zeitraum:
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen |
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Publication of the Pivotal Phase 2b ReNeu Trial Evaluating Mirdametinib in Adults and Children with NF1-PN in the Journal of Clinical ... | - Mirdametinib treatment demonstrated significant confirmed objective response rates and a manageable safety profile in adults and children with NF1-PN - - Patients achieved deep and durable reductions... ► Artikel lesen |
| SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Long-Term Efficacy and Safety Data from Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors to be Presented at ... | - Long-term follow-up data highlight further reductions in tumor size, increase in ORR with additional CRs, sustained improvement in desmoid tumor symptoms, and consistent safety profile, now with... ► Artikel lesen |
| EWTX Yields Over 300% Returns, ADMA Records 200% Gains - Did You Strike While The Iron Is Hot? | WASHINGTON (dpa-AFX) - Biotech investing is a high-stakes game that may not suit the faint-hearted due to its inherent volatility. However, this sector can offer astronomical returns when investors... ► Artikel lesen |
| ADMA Biologics, Inc.: ADMA Biologics Set to Join S&P SmallCap 600 Index | RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing... ► Artikel lesen |
| QIAGEN N.V.: Tiefere Erkenntnisse aus biologischen Proben: QIAGEN erweitert digitales PCR-System QIAcuity um Multiplexing-Funktionen höherer Ordnung | Digitales PCR-System QIAcuity ermöglicht nun gleichzeitigen Nachweis von bis zu zwölf Targets in einer biologischen Probe und damit mehr als das Doppelte der bisherigen fünf Targets
Keine... ► Artikel lesen |
| QIAGEN N.V.: QIAGEN Increases QIAcuity Digital PCR High-Order Multiplexing Capabilities to Gain Deeper Insights From Biological Samples | QIAcuity digital PCR now offers ability for simultaneous detection of up to 12 targets from one biological sample, a more than two-fold increase from prior capability for up to five targets
... ► Artikel lesen |
| Qiagen Gets U.S. Regulatory Clearance For QIAstat-Dx Gastrointestinal Panel Tests | AMSTERDAM (dpa-AFX) - Qiagen (QGEN) announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx Gastrointestinal Panel tests for clinical use.The clearance by the U.S. Food... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.
